Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06121297 · ClinicalTrials.gov registry record · Phase 1
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
A Phase 1 study of Systemic Lupus Erythematosus and Lupus Nephritis, sponsored by Cabaletta Bio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 20
- Study locations
NCT06121297: Recruiting Phase 1 study of Systemic Lupus Erythematosus and Lupus Nephritis, sponsored by Cabaletta Bio.
NCT06121297 is a Phase 1 study of Systemic Lupus Erythematosus and Lupus Nephritis that is actively recruiting participants, run by Cabaletta Bio. The registered enrollment target is 28 participants, below the 380-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06121297, a Phase 1 study of Systemic Lupus Erythematosus and Lupus Nephritis, is actively recruiting participants, sponsored by Cabaletta Bio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 20
- Study locations
Study Summary
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Conditions Studied
Interventions
- BIOLOGICAL CABA-201
Study Locations (20)
Massachusetts
- Tufts Medical Center - Boston
- Massachusetts General Hospital - Boston
- Boston Children's Hospital - Boston
- Brigham and Women's Hospital - Boston
- UMass Memorial Hospital - Worcester
California
- University of California Irvine - Orange
- UC Davis Health - Sacramento
Florida
- University of Florida Health - Gainesville
- Mayo Clinic - Jacksonville
Illinois
- Northwestern Memorial Hospital - Chicago
- The University of Chicago Medical Center - Chicago
New York
- Columbia University Irving Medical Center - New York
- University of Rochester - Rochester
Connecticut
- Yale University - New Haven
Georgia
- Emory University - Atlanta
Kansas
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2024-02-16 |
| Est. Completion | 2029-12 |
| Phase | Phase 1 |
What NCT06121297 shows while recruiting
NCT06121297 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 380-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 1 intervention - of which CABA-201 is the first listed.
NCT06121297 names 20 study sites across 12 states, led by Massachusetts, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06121297 about?
NCT06121297 is a clinical study titled "RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus". RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
What is the current status of trial NCT06121297?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2024-02-16. Estimated completion is 2029-12.
What conditions does trial NCT06121297 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus, Lupus Nephritis.
What interventions are being tested in trial NCT06121297?
The interventions under investigation include: CABA-201 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06121297?
This trial is sponsored by Cabaletta Bio, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06121297 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06121297's enrollment target sits among peer trials
28 85th of 99 higher than 15 of 99 other Systemic Lupus Erythematosus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Systemic Lupus Erythematosus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)
RECRUITING · Phase 1
-
A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus
RECRUITING · Phase 1
-
REACT-01: Reversing Autoimmunity Through Cell Therapy
RECRUITING · Phase 1
-
Alnuctamab for Refractory SLE (LATTE Study)
RECRUITING · Phase 1
-
BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus
RECRUITING · Phase 1
-
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI